For research use only. Not for therapeutic Use.
DAPTA (Peptide T)（Cat No.:R014117）is an octapeptide derived from the HIV envelope protein gp120, known for its role as a CCR5 receptor antagonist. It has been studied for its potential to block HIV entry into cells by inhibiting the interaction between the virus and the CCR5 co-receptor, thereby preventing viral replication. DAPTA has also shown promise in neuroprotection and inflammation regulation, particularly in conditions like HIV-associated neurocognitive disorders. Its non-toxic nature and ability to cross the blood-brain barrier make it a valuable candidate for research in HIV and neurodegenerative disease therapies.
| Catalog Number | R014117 |
| CAS Number | 106362-34-9 |
| Synonyms | D-Alanyl-L-seryl-L-threonyl-L-threonyl-L-threonyl-L-asparaginyl-L-tyrosyl-L-threoninamide; |
| Molecular Formula | C35H56N10O15 |
| Purity | ≥95% |
| Target | Chemokine Receptors |
| Solubility | Soluble to 1 mg/ml in sterile water |
| Storage | Desiccate at -20C |
| IUPAC Name | (2S)-N-[(2S)-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]butanediamide |
| InChI | InChI=1S/C35H56N10O15/c1-13(36)29(54)41-22(12-46)32(57)43-26(16(4)49)34(59)45-27(17(5)50)35(60)44-25(15(3)48)33(58)40-21(11-23(37)52)30(55)39-20(10-18-6-8-19(51)9-7-18)31(56)42-24(14(2)47)28(38)53/h6-9,13-17,20-22,24-27,46-51H,10-12,36H2,1-5H3,(H2,37,52)(H2,38,53)(H,39,55)(H,40,58)(H,41,54)(H,42,56)(H,43,57)(H,44,60)(H,45,59)/t13-,14-,15-,16-,17-,20+,21+,22+,24+,25+,26+,27+/m1/s1 |
| InChIKey | AKWRNBWMGFUAMF-ZESMOPTKSA-N |
| SMILES | C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)O |
| Reference | </br>1:trans-thionate derivatives of Pt(II) and Pd(II) with water-soluble phosphane PTA and DAPTA ligands: antiproliferative activity against human ovarian cancer cell lines. Guerrero E, Miranda S, Lüttenberg S, Fröhlich N, Koenen JM, Mohr F, Cerrada E, Laguna M, Mendía A.Inorg Chem. 2013 Jun 3;52(11):6635-47. doi: 10.1021/ic4006746. Epub 2013 May 21. PMID: 23692403 </br>2:Synthesis, characterization, and in vitro cytotoxicity of some gold(I) and trans platinum(II) thionate complexes containing water-soluble PTA and DAPTA ligands. X-ray crystal structures of [Au(SC4H3N2)(PTA)], trans-[Pt(SC4H3N2)2(PTA)2], trans-[Pt(SC5H4N)2(PTA)2], and trans-[Pt(SC5H4N)2(DAPTA)2]. Miranda S, Vergara E, Mohr F, de Vos D, Cerrada E, Mendía A, Laguna M.Inorg Chem. 2008 Jul 7;47(13):5641-8. doi: 10.1021/ic7021903. Epub 2008 Apr 30. PMID: 18447334 </br>3:Profound anti-HIV-1 activity of DAPTA in monocytes/macrophages and inhibition of CCR5-mediated apoptosis in neuronal cells. Pollicita M, Ruff MR, Pert CB, Polianova MT, Schols D, Ranazzi A, Perno CF, Aquaro S.Antivir Chem Chemother. 2007;18(5):285-95. PMID: 18046961 </br>4:Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Polianova MT, Ruscetti FW, Pert CB, Ruff MR.Antiviral Res. 2005 Aug;67(2):83-92. PMID: 16002156 </br>5:Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Ruff MR, Polianova M, Yang QE, Leoung GS, Ruscetti FW, Pert CB.Curr HIV Res. 2003 Jan;1(1):51-67. Review. PMID: 15043212 </br>6:Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA). Polianova MT, Ruscetti FW, Pert CB, Tractenberg RE, Leoung G, Strang S, Ruff MR.Peptides. 2003 Jul;24(7):1093-8. PMID: 14499289 |
